EWErika Wong

Erika Wong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Erika Wong has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Che-Chung Yeh

    Department of Anesthesia and Perioperative Care, University of California, San Francisco School of Medicine, San Francisco, CA 94143

    1 shared publication
  • Elliot Lloyd

    Department of Anesthesia and Perioperative Care, University of California, San Francisco School of Medicine, San Francisco, CA 94143

    1 shared publication
  • Fengyun Xu

    Department of Anesthesia and Perioperative Care, University of California, San Francisco School of Medicine, San Francisco, CA 94143

    1 shared publication
  • Ivana Zlatanova

    Cardiovascular Research Institute, University of California, San Francisco School of Medicine, San Francisco, CA 94158; and

    1 shared publication
  • Judith Hellman

    Department of Anesthesia and Perioperative Care, UCSF School of Medicine, San Francisco, California, USA

    1 shared publication
  • Jérémie Joffre

    Intensive Care Unit, Saint-Antoine University Hospital, APHP, Sorbonne University, Paris, France

    1 shared publication

Latest Publications

  • Open Access

    Activation of CB1R Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells and Reduces Acute Inflammation and Organ Injury

    by Jérémie Joffre, Che-Chung Yeh, Erika Wong, Mayuri Thete, Fengyun Xu, Ivana Zlatanova, Elliot Lloyd, Lester Kobzik, Matthieu Legrand, Judith Hellman

    Cannabis sativa and its principal components, Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol, are increasingly being used to treat a variety of medical problems, including inflammatory conditions. Although studies suggest that the endocannabinoid system has immunomodulatory properties, there remains a paucity of information on the effects of cannabinoids on immunity and on outcomes of infection and injury. We investigated the effects and mechanism(s) of action of cannabinoid receptor agonists, including Δ9-THC, on inflammation and organ injury in endotoxemic mice. Administration of Δ9-THC caused a dramatic early upregulation of plasma IL-10 levels, reduced plasma IL-6 and CCL-2 levels, led to better clinical status, and attenuated organ injury in endotoxemic mice. The anti-inflammatory effects of Δ9-THC in endotoxemic mice were reversed by a cannabinoid receptor type 1 (CB1R) inverse agonist (SR141716), and by clodronate-induced myeloid-cell depletion, but not by genetic invalidation or blockade of other putative Δ9-THC receptors, including cannabinoid receptor type 2, TRPV1, GPR18, GPR55, and GPR119. Although Δ9-THC administration reduced the activation of several spleen immune cell subsets, the anti-inflammatory effects of Δ9-THC were preserved in splenectomized endotoxemic mice. Finally, using IL-10–GFP reporter mice, we showed that blood monocytic myeloid-derived suppressive cells mediate the Δ9-THC–induced early rise in circulating IL-10. These results indicate that Δ9-THC potently induces IL-10, while reducing proinflammatory cytokines, chemokines, and related organ injury in endotoxemic mice via the activation of CB1R. These data have implications for acute and chronic conditions that are driven by dysregulated inflammation, such as sepsis, and raise the possibility that CB1R-signaling may constitute a novel target for inflammatory disorders. Key Points Δ9-THC increases IL-10 and reduces IL-6 and CCL2 in endotoxemic mice via CB1R. Δ9-THC decreases lung inflammation and organ injury in endotoxemic mice. Monocytic-MDSCs mediate Δ9-THC–induced IL-10 upregulation in endotoxemic mice.